The Immune Response Corporation, Inc. Announces That Previously Approved One-for-100 Reverse Stock Split Will Take Effect On December 20, 2006

CARLSBAD, Calif.--(BUSINESS WIRE)--The Immune Response Corporation (OTCBB:IMNR), an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases and HIV/AIDS, announced today that it will make a one-for-100 reverse stock split of its common stock. On a pre-split basis, Immune Response Corporation has approximately 900 million basic shares of common stock outstanding as of the end of trading on December 4, 2006. As a result of the reverse stock split, every 100 shares of common stock will be combined into one share of common stock and the total number of basic shares outstanding will be reduced to approximately 9 million.